15-min delayed · Aug 26, 8:00 AM ET · Get real-time quotes →
ANALYST CONSENSUS0 ratings
No Rating
Strong Buy00%
Buy00%
Hold00%
Sell00%
Strong Sell00%
Analyst rating coverage is not available for LYRA yet.
12-MONTH PRICE TARGET
—
Average analyst target vs $0.25 current
Highest Target—
Average Target—
Lowest Target—
LYRA analyst recommendation trends
86420
Aug
Sep
Oct
Nov
Dec
Jan
Feb
Mar
Apr
May
Jun
Jul
Strong BuyBuyHoldSellStrong Sell
RATING
FEB
MAR
APR
MAY
JUN
JUL
Strong Buy
0
0
0
0
0
0
Buy
0
0
0
0
0
0
Hold
1
1
1
1
1
1
Sell
0
0
0
0
0
0
Strong Sell
0
0
0
0
0
0
Total
1
1
1
1
1
1
As of Jul, 0 of 1 firms rate LYRA a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
LYRA EPS & revenue forecast
EPS · THIS QUARTER
$-7.14
Range $-7.14 – $-7.14 · 1 analysts · -11% YoY
Next period, 1 analysts expect Lyra Therapeutics Inc to earn $-7.14 a share (range $-7.14 – $-7.14), versus $-8.00 a year earlier. , growing to $-7.02 the year after.
REVENUE · THIS QUARTER
—
Range — – — · 1 analysts
Revenue is expected to reach — (range — – —)., rising to $700.0K next year.
Top analysts covering Lyra Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on LYRA.
#1
MC
Matthew Caufield
HC Wainwright & Co. · Rank #87
Hold
$16.00+6300.0% to target
Overall win rate
54%
+ Follow
#2
Justin Zelin
BTIG
Hold
No targeton LYRA
Coverage
—
+ Follow
#3
LH
Lachlan Hanbury Brown
William Blair
Hold
No targeton LYRA
Coverage
—
+ Follow
#4
DD
Dennis Ding
Jefferies
Hold
$30.00+11900.0% to target
Coverage
—
+ Follow
LYRA stock forecast FAQ
Who is the most accurate analyst covering LYRA?+
Among analysts who currently cover LYRA, Matthew Caufield of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #87). Their current call is Hold with a $16.00 target.
What is Lyra Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-7.14 per share (range $-7.14 – $-7.14) across 1 analysts, rising to $-7.02 the following year.
How much revenue is Lyra Therapeutics Inc expected to report next quarter?+
Consensus revenue is — (range — – —), growing to $700.0K next year.
Have analysts been upgrading or downgrading LYRA lately?+
As of Jul, 0 of 1 firms rate LYRA a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their LYRA calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
